Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business
  2. Companies
  3. Medical / Health Care
  4. Medical Monitoring
  5. RTI Group AB

Intrommune Therapeutics Names Nandini Murthy as Head of Regulatory

SHARE
May. 31, 2022
Courtesy ofIntrommune Therapeutics

NEW YORK, June 01, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced the addition of Nandini Murthy as Head of Regulatory.

“Ms. Murthy has proven to be an invaluable asset to Intrommune since joining the organization as a consultant working with our regulatory and clinical development teams,” said Michael Nelson, CEO, Intrommune Therapeutics. “Ms. Murthy’s agreement to join our Leadership Team as Head of Regulatory is a testament to her commitment to helping patients with food allergies live better lives and her expertise in regulatory, clinical and quality affairs is a valuable addition to Intrommune as we progress our patient friendly treatment for peanut allergy, INT301 and our follow-on food allergy products.”

The Company’s oral mucosal immunotherapy (OMIT) platform is based on the well-accepted principles of allergy immunotherapy. The company’s initial product, INT301, is an immunotherapy treatment for peanut allergy delivered via a specially-formulated toothpaste designed to optimize exposure of allergenic proteins to a patient’s immune system while also cleaning their teeth. Intrommune is currently enrolling patients into its INT301 Phase 1 OMEGA clinical trial.

Ms. Murthy joins Intrommune with significant strategic and operational experience across regulatory affairs, clinical and quality assurance functions. Over the past 25+ years in full time or consulting roles, she has led numerous, successful FDA submissions for novel combination and device clearances or approvals. As founder of a boutique life sciences consulting firm, ENEM Consulting LLC, her successful track record in novel therapeutics and diagnostics regulatory projects includes drug delivery systems and GRAS drug/botanical products.

“I am honored to be working on this novel platform of food allergy treatments with the hope that these products will help patients with food allergies live better lives,” said Nandini Murthy, Head of Regulatory, Intrommune.

Contact supplier

Drop file here or browse